小儿肺咳颗粒治疗急性支气管炎的有效性与安全性:系统评价与Meta分析
该系统评价纳入20项RCT共2482例患儿,比较小儿肺咳颗粒联合西药与单用西药治疗急性支气管炎的疗效与安全性。Meta分析显示联合治疗在缩短咳嗽、发热、喘息等症状消失时间及住院时间、减少抗生素使用天数、降低炎症因子等方面优于单用西药,且未增加不良反应风险,但证据质量多为低至极低。
要点
- 小儿肺咳颗粒联合西药可缩短急性支气管炎患儿咳嗽、发热、喘息等症状消失时间。
- 联合治疗可减少抗生素使用天数并降低TNF-α、CRP、IL-6、PCT水平。
- 联合治疗未增加总体不良反应及恶心呕吐、腹泻、皮疹、头晕的发生风险。
核心结论
- 小儿肺咳颗粒联合西药治疗儿童急性支气管炎在疗效上优于单用西药,且不增加西药治疗相关的安全风险。
- 仍需设计良好的临床试验进一步验证。
研究设计与样本
- 系统评价与Meta分析,检索3个英文数据库和4个中文数据库至2023年12月31日。
- 纳入20项比较小儿肺咳颗粒联合西药与单用西药的RCT,共2482例患儿。
- 使用RevMan 5.4进行Meta分析,Stata 12.0评估发表偏倚,GRADE评估证据确定性。
- PROSPERO注册号CRD42023415479。
主要发现
- 咳嗽消失时间MD=-1.92天,95%CI(-2.36,-1.47),I2=97%,P<0.00001,证据确定性极低。
- 发热消失时间MD=-1.68天,95%CI(-2.21,-1.14),I2=99%,P<0.00001,证据确定性低。
- 喘息消失时间MD=-1.82天,95%CI(-2.01,-1.63),I2=0%,P<0.00001,证据确定性低。
- 肺部啰音消失时间MD=-1.68天,95%CI(-2.04,-1.31),I2=94%,P<0.00001,证据确定性极低。
- 咳痰消失时间MD=-1.45天,95%CI(-2.27,-0.63),I2=98%,P=0.0005<0.001,证据确定性极低。
关键数值与推荐
- 小儿肺咳颗粒联合西药对比单用西药:咳嗽消失时间MD=-1.92天,95%CI(-2.36,-1.47),证据确定性极低。
- 发热消失时间MD=-1.68天,95%CI(-2.21,-1.14),证据确定性低。
- 喘息消失时间MD=-1.82天,95%CI(-2.01,-1.63),证据确定性低。
- 抗生素使用时间MD=-2.81天,95%CI(-3.09,-2.53),证据确定性低。
- 不良反应发生率组间差异无统计学意义(P>0.05)。
临床怎么用
- 在儿童急性支气管炎治疗中,可考虑小儿肺咳颗粒联合常规西药以缩短症状消失时间和抗生素使用天数。
- 联合用药未增加总体不良反应风险,但需注意证据确定性多为低至极低,临床决策应结合具体情况。
局限性
- 多数结局指标证据确定性为低或极低。
- 部分结局异质性高(如咳嗽I2=97%,发热I2=99%)。
- 原文指出仍需设计良好的临床试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Xiao'er Feike Granules (XFG), containing eighteen incompatibilities, is an approved and widely used classical Chinese medicine prescription for the treatment of pediatric respiratory diseases. Extensive clinical studies have reported that XFG demonstrates high efficacy and minimal adverse reactions in treating acute bronchitis (AB). However, there is an urgent need for a more cohesive evaluation of the evidence regarding the safe clinical use of XFG for AB. A clearer and more systematic summary of relevant randomized controlled trials (RCTs) is necessary to assess the overall efficacy and safety of XFG. AIM OF THE STUDY: To assess the efficacy and safety of XFG for oral administration in treating AB. MATERIALS AND METHODS: RCTs comparing XFG (experimental group) with traditional Western medicine (TWM, control group) for the treatment of AB were collected by searching three English databases and four Chinese databases up to December 31, 2023. A meta-analysis was conducted by using RevMan 5.4 software, and potential publication bias was assessed by using Stata 12.0. A Grading of Recommendations Assessment, Development, and Evaluation (GRADE) evidence profile was constructed to evaluate the certainty of the evidence. RESULTS: A total of 2482 children were enrolled in 20 RCTs. The results of the meta-analysis indicated that XFG in combation with TWM is more effective than TWM alone in reducing the disappearance time of cough [MD = -1.92 days, 95% CI (-2.36, -1.47), I2 = 97%, P < 0.00001, very low certainty], fever [MD = -1.68 days, 95% CI (-2.21, -1.14), I2 = 99%, P < 0.00001, low certainty], wheezing [MD = -1.82 days, 95% CI (-2.01, -1.63), I2 = 0%, P < 0.00001, low certainty], lung rales [MD = -1.68 days, 95% CI (-2.04, -1.31), I2 = 94%, P < 0.00001, very low certainty], expectoration [MD = -1.45 days, 95% CI (-2.27, -0.63), I2 = 98%, P = 0.0005 < 0.001, very low certainty], and phlegm sounds [MD = -0.92 days, 95% CI (-1.10, -0.74), I2 = 38%, P < 0.00001, low certainty]. Additionally, shorter cure time [MD = -2.71 days, 95% CI (-3.32, -2.11), I2 = 84%, P < 0.00001, very low certainty] and the time of antibiotics use [MD = -2.81 days, 95% CI (-3.09, -2.53), I2 = 37%, P < 0.00001, low certainty], lower levels of inflammatory factors such as TNF-α [SMD = -3.53, 95% CI (-5.05, -2.01), I2 = 97%, P < 0.00001, very low certainty], CRP [SMD = -4.95, 95% CI (-6.56, -3.34), I2 = 97%, P < 0.00001, very low certainty], IL-6 [SMD = -2.95, 95% CI (-3.49, -2.40), I2 = 67%, P < 0.00001, very low certainty], and PCT [MD = -1.26 μg/L, 95% CI (-1.28, -1.24), I2 = 98%, P < 0.00001, very low certainty], as well as improved FEV1 [MD = 0.53 L, 95% CI (0.25, 0.80), I2 = 96%, P = 0.0002, very low certainty] after treatment. There was no statistically significant difference between the groups in levels of the IL-8, FEV1/FVC, FVC, CD4+, CD8+, and CD4+/CD8+ ratio. Additionally, no significant differences were observed in the incidences of overall adverse reactions, nausea and vomiting, diarrhea, rash, and dizziness (P > 0.05). CONCLUSION: XFG provides benefits to children with AB regarding its effectiveness and does not increase the safety risks associated with TWM treatment. However, well-designed clinical trials are still essential. TRIAL REGISTRATION: PROSPERO registration number: CRD42023415479.
引用
- Cao C, Liu X, Xu X, et al. The effectiveness and safety of Xiao'er Feike granules in the treatment of acute bronchitis: A systematic review and meta-analysis. J Ethnopharmacol. 2025. PMID: 39837358. doi:10.1016/j.jep.2025.119379
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。